-
K.
Muro,
E.
Cutsem,
Y.
Narita,
G.
Pentheroudakis,
E.
Baba,
J.
Li,
M.
Ryu,
W.
Zamaniah,
W.
Yong,
K.
Yeh,
K.
Kato,
Z.
Lu,
B.
Cho,
I.
Nor,
M.
Ng,
L.
Chen,
T.
Nakajima,
K.
Shitara,
H.
Kawakami,
T.
Tsushima,
T.
Yoshino,
F.
Lordick,
E.
Martinelli,
E.
Smyth,
D.
Arnold,
H.
Minami,
J.
Tabernero,
J.
Douillard
(2019)
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
Annals of Oncology, 30
-
D.
D’Ugo,
F.
Cananzi,
R.
Persiani,
A.
Agnes,
A.
Biondi
(2016)
REGATTA trial: a call for the USA and Europe.
The Lancet. Oncology, 17 3
-
(
FujitaniK
YangHK
MizusawaJ
, et al. Gastrectomy plus
chemotherapy versus chemotherapy alone for advanced gastric cancer with a
single non-curable factor (REGATTA): a phase 3, randomised controlled
trial. Lancet Oncol
2016; 17:
309–318.26822397)
FujitaniK
YangHK
MizusawaJ
, et al. Gastrectomy plus
chemotherapy versus chemotherapy alone for advanced gastric cancer with a
single non-curable factor (REGATTA): a phase 3, randomised controlled
trial. Lancet Oncol
2016; 17:
309–318.26822397
FujitaniK
YangHK
MizusawaJ
, et al. Gastrectomy plus
chemotherapy versus chemotherapy alone for advanced gastric cancer with a
single non-curable factor (REGATTA): a phase 3, randomised controlled
trial. Lancet Oncol
2016; 17:
309–318.26822397,
FujitaniK
YangHK
MizusawaJ
, et al. Gastrectomy plus
chemotherapy versus chemotherapy alone for advanced gastric cancer with a
single non-curable factor (REGATTA): a phase 3, randomised controlled
trial. Lancet Oncol
2016; 17:
309–318.26822397
-
(
CoccoliniF
CotteE
GlehenO
, et al. Intraperitoneal chemotherapy
in advanced gastric cancer. Meta-analysis of randomized
trials. Eur J Surg Oncol
2014; 40:
12–26.24290371)
CoccoliniF
CotteE
GlehenO
, et al. Intraperitoneal chemotherapy
in advanced gastric cancer. Meta-analysis of randomized
trials. Eur J Surg Oncol
2014; 40:
12–26.24290371
CoccoliniF
CotteE
GlehenO
, et al. Intraperitoneal chemotherapy
in advanced gastric cancer. Meta-analysis of randomized
trials. Eur J Surg Oncol
2014; 40:
12–26.24290371,
CoccoliniF
CotteE
GlehenO
, et al. Intraperitoneal chemotherapy
in advanced gastric cancer. Meta-analysis of randomized
trials. Eur J Surg Oncol
2014; 40:
12–26.24290371
-
(
SasakoM
SanoT
YamamotoS
, et al. Left thoracoabdominal
approach versus abdominal-transhiatal approach for gastric cancer of the
cardia or subcardia: a randomised controlled trial.
Lancet Oncol
2006; 7:
644–651.16887481)
SasakoM
SanoT
YamamotoS
, et al. Left thoracoabdominal
approach versus abdominal-transhiatal approach for gastric cancer of the
cardia or subcardia: a randomised controlled trial.
Lancet Oncol
2006; 7:
644–651.16887481
SasakoM
SanoT
YamamotoS
, et al. Left thoracoabdominal
approach versus abdominal-transhiatal approach for gastric cancer of the
cardia or subcardia: a randomised controlled trial.
Lancet Oncol
2006; 7:
644–651.16887481,
SasakoM
SanoT
YamamotoS
, et al. Left thoracoabdominal
approach versus abdominal-transhiatal approach for gastric cancer of the
cardia or subcardia: a randomised controlled trial.
Lancet Oncol
2006; 7:
644–651.16887481
-
J.
Mezhir,
M.
Shah,
L.
Jacks,
M.
Brennan,
D.
Coit,
V.
Strong
(2011)
Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients
Indian Journal of Surgical Oncology, 2
-
E.
Smyth,
M.
Verheij,
W.
Allum,
D.
Cunningham,
A.
Cervantes,
D.
Arnold
(2010)
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 Suppl 5
-
(
HegerU
BlankS
WiechaC
, et al. Is preoperative chemotherapy
followed by surgery the appropriate treatment for signet ring cell
containing adenocarcinomas of the esophagogastric junction and
stomach?
Ann Surg Oncol
2014; 21:
1739–1748.24419755)
HegerU
BlankS
WiechaC
, et al. Is preoperative chemotherapy
followed by surgery the appropriate treatment for signet ring cell
containing adenocarcinomas of the esophagogastric junction and
stomach?
Ann Surg Oncol
2014; 21:
1739–1748.24419755
HegerU
BlankS
WiechaC
, et al. Is preoperative chemotherapy
followed by surgery the appropriate treatment for signet ring cell
containing adenocarcinomas of the esophagogastric junction and
stomach?
Ann Surg Oncol
2014; 21:
1739–1748.24419755,
HegerU
BlankS
WiechaC
, et al. Is preoperative chemotherapy
followed by surgery the appropriate treatment for signet ring cell
containing adenocarcinomas of the esophagogastric junction and
stomach?
Ann Surg Oncol
2014; 21:
1739–1748.24419755
-
Sid
Kerkar,
Clinton
Kemp,
Austin
Duffy,
U.
Kammula,
D.
Schrump,
King
Kwong,
Martha
Quezado,
Barry
Goldspiel,
Aradhana
Venkatesan,
Ann
Berger,
Melissa
Walker,
M.
Toomey,
Seth
Steinberg,
Guiseppe
Giaccone,
Steven
Rosenberg,
Itzhak
Avital
(2009)
The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone
Trials, 10
-
J.
Ajani,
T.
D’amico,
K.
Almhanna,
D.
Bentrem,
J.
Chao,
P.
Das,
C.
Denlinger,
P.
Fanta,
F.
Farjah,
C.
Fuchs,
H.
Gerdes,
M.
Gibson,
R.
Glasgow,
J.
Hayman,
S.
Hochwald,
W.
Hofstetter,
D.
Ilson,
D.
Jaroszewski,
K.
Johung,
R.
Keswani,
L.
Kleinberg,
W.
Korn,
S.
Leong,
Catherine
Linn,
A.
Lockhart,
Quan
Ly,
M.
Mulcahy,
M.
Orringer,
K.
Perry,
G.
Poultsides,
W.
Scott,
V.
Strong,
M.
Washington,
B.
Weksler,
C.
Willett,
C.
Wright,
Debra
Zelman,
Nicole
Mcmillian,
Hema
Sundar
(2016)
Gastric Cancer, Version 3.2016, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN, 14 10
-
E.
Cutsem,
V.
Moiseyenko,
S.
Tjulandin,
A.
Majlis,
M.
Constenla,
C.
Boni,
Adriano
Rodrigues,
M.
Fodor,
Y.
Chao,
E.
Voznyi,
M.
Risse,
J.
Ajani
(2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 31
-
(
de GaraCJ
HansonJ
HamiltonS
. A population-based study of tumor-node
relationship, resection margins, and surgeon volume on gastric cancer
survival. Am J Surg
2003; 186:
23–27.12842743)
de GaraCJ
HansonJ
HamiltonS
. A population-based study of tumor-node
relationship, resection margins, and surgeon volume on gastric cancer
survival. Am J Surg
2003; 186:
23–27.12842743
de GaraCJ
HansonJ
HamiltonS
. A population-based study of tumor-node
relationship, resection margins, and surgeon volume on gastric cancer
survival. Am J Surg
2003; 186:
23–27.12842743,
de GaraCJ
HansonJ
HamiltonS
. A population-based study of tumor-node
relationship, resection margins, and surgeon volume on gastric cancer
survival. Am J Surg
2003; 186:
23–27.12842743
-
Lu-Ping
Yang,
Zixian
Wang,
M.
He,
Ying
Jin,
C.
Ren,
Zhi-Qiang
Wang,
Fenghua
Wang,
Yu-hong
Li,
Feng
Wang,
R.
Xu
(2019)
The survival benefit of palliative gastrectomy and/or metastasectomy in gastric cancer patients with synchronous metastasis: a population-based study using propensity score matching and coarsened exact matching
Journal of Cancer, 10
-
Lei
Huang,
L.
Jansen,
Y.
Balavarca,
R.
Verhoeven,
J.
Ruurda,
L.
Eycken,
H.
Schutter,
J.
Johansson,
M.
Lindblad,
T.
Johannesen,
V.
Zadnik,
T.
Žagar,
M.
Mägi,
E.
Bastiaannet,
S.
Lagarde,
C.
Velde,
P.
Schrotz-King,
H.
Brenner
(2020)
Decreasing resection rates for nonmetastatic gastric cancer in Europe and the United States
Clinical and Translational Medicine, 10
-
Lei
Huang,
L.
Jansen,
Y.
Balavarca,
E.
Molina-Montes,
M.
Babaei,
L.
Geest,
V.
Lemmens,
L.
Eycken,
H.
Schutter,
T.
Johannesen,
C.
Fristrup,
M.
Mortensen,
M.
Primic‐Žakelj,
V.
Zadnik,
N.
Becker,
T.
Hackert,
M.
Mägi,
T.
Cassetti,
R.
Sassatelli,
R.
Grützmann,
S.
Merkel,
A.
Gonçalves,
M.
Bento,
P.
Hegyi,
G.
Lakatos,
A.
Szentesi,
M.
Moreau,
T.
Velde,
A.
Broeks,
M.
Sant,
P.
Minicozzi,
V.
Mazzaferro,
F.
Real,
A.
Carrato,
X.
Molero,
M.
Besselink,
N.
Malats,
M.
Büchler,
P.
Schrotz-King,
H.
Brenner
(2017)
Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations
Gut, 68
-
U.
Heger,
S.
Blank,
Christiane
Wiecha,
R.
Langer,
W.
Weichert,
F.
Lordick,
T.
Bruckner,
M.
Dobritz,
M.
Burian,
C.
Springfeld,
L.
Grenacher,
J.
Siewert,
M.
Büchler,
K.
Ott
(2014)
Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach?
Annals of Surgical Oncology, 21
-
(
ZhangJZ
LuHS
HuangCM
, et al. Outcome of palliative total
gastrectomy for stage IV proximal gastric cancer. Am
J Surg
2011; 202:
91–96.21600557)
ZhangJZ
LuHS
HuangCM
, et al. Outcome of palliative total
gastrectomy for stage IV proximal gastric cancer. Am
J Surg
2011; 202:
91–96.21600557
ZhangJZ
LuHS
HuangCM
, et al. Outcome of palliative total
gastrectomy for stage IV proximal gastric cancer. Am
J Surg
2011; 202:
91–96.21600557,
ZhangJZ
LuHS
HuangCM
, et al. Outcome of palliative total
gastrectomy for stage IV proximal gastric cancer. Am
J Surg
2011; 202:
91–96.21600557
-
(
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
in 185 countries. CA Cancer J Clin
2018; 68:
394–424.30207593)
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
in 185 countries. CA Cancer J Clin
2018; 68:
394–424.30207593
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
in 185 countries. CA Cancer J Clin
2018; 68:
394–424.30207593,
BrayF
FerlayJ
SoerjomataramI
, et al. Global cancer statistics
2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers
in 185 countries. CA Cancer J Clin
2018; 68:
394–424.30207593
-
D.
Spiegelman,
E.
Hertzmark
(2005)
Easy SAS calculations for risk or prevalence ratios and differences.
American journal of epidemiology, 162 3
-
U.
Rudloff,
R.
Langan,
J.
Mullinax,
J.
Beane,
S.
Steinberg,
T.
Beresnev,
Carole
Webb,
M.
Walker,
M.
Toomey,
D.
Schrump,
P.
Pandalai,
A.
Stojadinovic,
I.
Avital
(2014)
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial
Journal of Surgical Oncology, 110
-
(
YoshinoT
ArnoldD
TaniguchiH
, et al. Pan-Asian adapted ESMO
consensus guidelines for the management of patients with metastatic
colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO
and TOS. Ann Oncol
2018; 29:
44–70.29155929)
YoshinoT
ArnoldD
TaniguchiH
, et al. Pan-Asian adapted ESMO
consensus guidelines for the management of patients with metastatic
colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO
and TOS. Ann Oncol
2018; 29:
44–70.29155929
YoshinoT
ArnoldD
TaniguchiH
, et al. Pan-Asian adapted ESMO
consensus guidelines for the management of patients with metastatic
colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO
and TOS. Ann Oncol
2018; 29:
44–70.29155929,
YoshinoT
ArnoldD
TaniguchiH
, et al. Pan-Asian adapted ESMO
consensus guidelines for the management of patients with metastatic
colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO
and TOS. Ann Oncol
2018; 29:
44–70.29155929
-
(
KerkarSP
KempCD
DuffyA
, et al. The GYMSSA trial: a
prospective randomized trial comparing gastrectomy, metastasectomy plus
systemic therapy versus systemic therapy alone.
Trials
2009; 10: 121.20030854)
KerkarSP
KempCD
DuffyA
, et al. The GYMSSA trial: a
prospective randomized trial comparing gastrectomy, metastasectomy plus
systemic therapy versus systemic therapy alone.
Trials
2009; 10: 121.20030854
KerkarSP
KempCD
DuffyA
, et al. The GYMSSA trial: a
prospective randomized trial comparing gastrectomy, metastasectomy plus
systemic therapy versus systemic therapy alone.
Trials
2009; 10: 121.20030854,
KerkarSP
KempCD
DuffyA
, et al. The GYMSSA trial: a
prospective randomized trial comparing gastrectomy, metastasectomy plus
systemic therapy versus systemic therapy alone.
Trials
2009; 10: 121.20030854
-
Qin
Li,
Jiahua
Zou,
M.
Jia,
Ping
Li,
Rui
Zhang,
Jianglong
Han,
Kejie
Huang,
Yunfeng
Qiao,
Tangpeng
Xu,
R.
Peng,
Q.
Song,
Zhenming
Fu
(2019)
Palliative Gastrectomy and Survival in Patients With Metastatic Gastric Cancer: A Propensity Score–Matched Analysis of a Large Population-Based Study
Clinical and Translational Gastroenterology, 10
-
Z.
Khazaei,
A.
Jarrahi,
V.
Momenabadi,
F.
Ghorat,
H.
Adineh,
Malihe
Sohrabivafa,
E.
Goodarzi
(2019)
GLOBAL CANCER STATISTICS 2018: GLOBOCAN ESTIMATES OF INCIDENCE AND MORTALITY WORLDWIDE STOMACH CANCERS AND THEIR RELATIONSHIP WITH THE HUMAN DEVELOPMENT INDEX (HDI)
-
(
Surveillance, Epidemiology, and End Results (SEER) Program.
Research Data (1973-2016), National Cancer Institute, DCCPS,
Surveillance Research Program, https://seer.cancer.gov/
(2019, accessed 30 May
2018).)
Surveillance, Epidemiology, and End Results (SEER) Program.
Research Data (1973-2016), National Cancer Institute, DCCPS,
Surveillance Research Program, https://seer.cancer.gov/
(2019, accessed 30 May
2018).
Surveillance, Epidemiology, and End Results (SEER) Program.
Research Data (1973-2016), National Cancer Institute, DCCPS,
Surveillance Research Program, https://seer.cancer.gov/
(2019, accessed 30 May
2018).,
Surveillance, Epidemiology, and End Results (SEER) Program.
Research Data (1973-2016), National Cancer Institute, DCCPS,
Surveillance Research Program, https://seer.cancer.gov/
(2019, accessed 30 May
2018).
-
(
YangLP
WangZX
HeMM
, et al. The survival benefit of
palliative gastrectomy and/or metastasectomy in gastric cancer patients with
synchronous metastasis: a population-based study using propensity score
matching and coarsened exact matching. J
Cancer
2019; 10:
602–610.30719157)
YangLP
WangZX
HeMM
, et al. The survival benefit of
palliative gastrectomy and/or metastasectomy in gastric cancer patients with
synchronous metastasis: a population-based study using propensity score
matching and coarsened exact matching. J
Cancer
2019; 10:
602–610.30719157
YangLP
WangZX
HeMM
, et al. The survival benefit of
palliative gastrectomy and/or metastasectomy in gastric cancer patients with
synchronous metastasis: a population-based study using propensity score
matching and coarsened exact matching. J
Cancer
2019; 10:
602–610.30719157,
YangLP
WangZX
HeMM
, et al. The survival benefit of
palliative gastrectomy and/or metastasectomy in gastric cancer patients with
synchronous metastasis: a population-based study using propensity score
matching and coarsened exact matching. J
Cancer
2019; 10:
602–610.30719157
-
(
MessagerM
LefevreJH
Pichot-DelahayeV
, et al. The impact of perioperative
chemotherapy on survival in patients with gastric signet ring cell
adenocarcinoma: a multicenter comparative study. Ann
Surg
2011; 254: 684–693;
discussion 93.22005144)
MessagerM
LefevreJH
Pichot-DelahayeV
, et al. The impact of perioperative
chemotherapy on survival in patients with gastric signet ring cell
adenocarcinoma: a multicenter comparative study. Ann
Surg
2011; 254: 684–693;
discussion 93.22005144
MessagerM
LefevreJH
Pichot-DelahayeV
, et al. The impact of perioperative
chemotherapy on survival in patients with gastric signet ring cell
adenocarcinoma: a multicenter comparative study. Ann
Surg
2011; 254: 684–693;
discussion 93.22005144,
MessagerM
LefevreJH
Pichot-DelahayeV
, et al. The impact of perioperative
chemotherapy on survival in patients with gastric signet ring cell
adenocarcinoma: a multicenter comparative study. Ann
Surg
2011; 254: 684–693;
discussion 93.22005144
-
(
RudloffU
LanganRC
MullinaxJE
, et al. Impact of maximal
cytoreductive surgery plus regional heated intraperitoneal chemotherapy
(HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric
origin: results of the GYMSSA trial. J Surg
Oncol
2014; 110:
275–284.25042700)
RudloffU
LanganRC
MullinaxJE
, et al. Impact of maximal
cytoreductive surgery plus regional heated intraperitoneal chemotherapy
(HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric
origin: results of the GYMSSA trial. J Surg
Oncol
2014; 110:
275–284.25042700
RudloffU
LanganRC
MullinaxJE
, et al. Impact of maximal
cytoreductive surgery plus regional heated intraperitoneal chemotherapy
(HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric
origin: results of the GYMSSA trial. J Surg
Oncol
2014; 110:
275–284.25042700,
RudloffU
LanganRC
MullinaxJE
, et al. Impact of maximal
cytoreductive surgery plus regional heated intraperitoneal chemotherapy
(HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric
origin: results of the GYMSSA trial. J Surg
Oncol
2014; 110:
275–284.25042700
-
S.
Thrumurthy,
M.
Chaudry,
D.
Hochhauser,
Kathleen
Ferrier,
M.
Mughal
(2013)
The diagnosis and management of gastric cancer
BMJ : British Medical Journal, 347
-
(
Japanese Gastric Cancer Association. Japanese
gastric cancer treatment guidelines 2014 (ver. 4).
Gastric Cancer
2017; 20:
1–19.)
Japanese Gastric Cancer Association. Japanese
gastric cancer treatment guidelines 2014 (ver. 4).
Gastric Cancer
2017; 20:
1–19.
Japanese Gastric Cancer Association. Japanese
gastric cancer treatment guidelines 2014 (ver. 4).
Gastric Cancer
2017; 20:
1–19.,
Japanese Gastric Cancer Association. Japanese
gastric cancer treatment guidelines 2014 (ver. 4).
Gastric Cancer
2017; 20:
1–19.
-
(
CunninghamD
StarlingN
RaoS
, et al. Capecitabine and oxaliplatin
for advanced esophagogastric cancer. N Engl J
Med
2008; 358:
36–46.18172173)
CunninghamD
StarlingN
RaoS
, et al. Capecitabine and oxaliplatin
for advanced esophagogastric cancer. N Engl J
Med
2008; 358:
36–46.18172173
CunninghamD
StarlingN
RaoS
, et al. Capecitabine and oxaliplatin
for advanced esophagogastric cancer. N Engl J
Med
2008; 358:
36–46.18172173,
CunninghamD
StarlingN
RaoS
, et al. Capecitabine and oxaliplatin
for advanced esophagogastric cancer. N Engl J
Med
2008; 358:
36–46.18172173
-
R.
Kwee,
T.
Kwee
(2007)
Imaging in local staging of gastric cancer: a systematic review.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 15
-
(
KweeRM
KweeTC
. Imaging in local staging of gastric cancer: a
systematic review. J Clin Oncol
2007; 25:
2107–2116.17513817)
KweeRM
KweeTC
. Imaging in local staging of gastric cancer: a
systematic review. J Clin Oncol
2007; 25:
2107–2116.17513817
KweeRM
KweeTC
. Imaging in local staging of gastric cancer: a
systematic review. J Clin Oncol
2007; 25:
2107–2116.17513817,
KweeRM
KweeTC
. Imaging in local staging of gastric cancer: a
systematic review. J Clin Oncol
2007; 25:
2107–2116.17513817
-
O.
Bouché,
J.
Raoul,
F.
Bonnetain,
M.
Giovannini,
P.
Etienne,
G.
Lledo,
D.
Arsène,
J.
Paitel,
V.
Guérin-Meyer,
E.
Mitry,
B.
Buecher,
M.
Kaminsky,
J.
Seitz,
P.
Rougier,
L.
Bedenne,
C.
Milan
(2004)
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancerologie Digestive Group Study--FFCD 9803.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 21
-
(
MuroK
Van CutsemE
NaritaY
, et al. Pan-Asian adapted ESMO
clinical practice guidelines for the management of patients with metastatic
gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and
TOS. Ann Oncol
2019; 30:
19–33.30475956)
MuroK
Van CutsemE
NaritaY
, et al. Pan-Asian adapted ESMO
clinical practice guidelines for the management of patients with metastatic
gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and
TOS. Ann Oncol
2019; 30:
19–33.30475956
MuroK
Van CutsemE
NaritaY
, et al. Pan-Asian adapted ESMO
clinical practice guidelines for the management of patients with metastatic
gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and
TOS. Ann Oncol
2019; 30:
19–33.30475956,
MuroK
Van CutsemE
NaritaY
, et al. Pan-Asian adapted ESMO
clinical practice guidelines for the management of patients with metastatic
gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and
TOS. Ann Oncol
2019; 30:
19–33.30475956
-
(
WarschkowR
BaechtoldM
LeungK
, et al. Selective survival advantage
associated with primary tumor resection for metastatic gastric cancer in a
Western population. Gastric Cancer
2018; 21:
324–337.28646258)
WarschkowR
BaechtoldM
LeungK
, et al. Selective survival advantage
associated with primary tumor resection for metastatic gastric cancer in a
Western population. Gastric Cancer
2018; 21:
324–337.28646258
WarschkowR
BaechtoldM
LeungK
, et al. Selective survival advantage
associated with primary tumor resection for metastatic gastric cancer in a
Western population. Gastric Cancer
2018; 21:
324–337.28646258,
WarschkowR
BaechtoldM
LeungK
, et al. Selective survival advantage
associated with primary tumor resection for metastatic gastric cancer in a
Western population. Gastric Cancer
2018; 21:
324–337.28646258
-
(
HuangL
JansenL
BalavarcaY
, et al. Resection of pancreatic
cancer in Europe and USA: an international large-scale study highlighting
large variations. Gut
2019; 68:
130–139.29158237)
HuangL
JansenL
BalavarcaY
, et al. Resection of pancreatic
cancer in Europe and USA: an international large-scale study highlighting
large variations. Gut
2019; 68:
130–139.29158237
HuangL
JansenL
BalavarcaY
, et al. Resection of pancreatic
cancer in Europe and USA: an international large-scale study highlighting
large variations. Gut
2019; 68:
130–139.29158237,
HuangL
JansenL
BalavarcaY
, et al. Resection of pancreatic
cancer in Europe and USA: an international large-scale study highlighting
large variations. Gut
2019; 68:
130–139.29158237
-
(
CharalampakisN
Nogueras GonzalezGM
ElimovaE
, et al. The proportion of signet
ring cell component in patients with localized gastric adenocarcinoma
correlates with the degree of response to pre-operative
chemoradiation. Oncology
2016; 90:
239–247.27046280)
CharalampakisN
Nogueras GonzalezGM
ElimovaE
, et al. The proportion of signet
ring cell component in patients with localized gastric adenocarcinoma
correlates with the degree of response to pre-operative
chemoradiation. Oncology
2016; 90:
239–247.27046280
CharalampakisN
Nogueras GonzalezGM
ElimovaE
, et al. The proportion of signet
ring cell component in patients with localized gastric adenocarcinoma
correlates with the degree of response to pre-operative
chemoradiation. Oncology
2016; 90:
239–247.27046280,
CharalampakisN
Nogueras GonzalezGM
ElimovaE
, et al. The proportion of signet
ring cell component in patients with localized gastric adenocarcinoma
correlates with the degree of response to pre-operative
chemoradiation. Oncology
2016; 90:
239–247.27046280
-
Research Data (1973-2016), National Cancer Institute, DCCPS, Surveillance Research Program
-
M.
Sasako,
T.
Sano,
Seiichiro
Yamamoto,
M.
Sairenji,
K.
Arai,
T.
Kinoshitá,
A.
Nashimoto,
M.
Hiratsuka
(2006)
Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial.
The Lancet. Oncology, 7 8
-
(
AjaniJA
D’AmicoTA
AlmhannaK
, et al. Gastric cancer, version
3.2016, NCCN clinical practice guidelines in oncology.
J Natl Compr Canc Netw
2016; 14:
1286–1312.27697982)
AjaniJA
D’AmicoTA
AlmhannaK
, et al. Gastric cancer, version
3.2016, NCCN clinical practice guidelines in oncology.
J Natl Compr Canc Netw
2016; 14:
1286–1312.27697982
AjaniJA
D’AmicoTA
AlmhannaK
, et al. Gastric cancer, version
3.2016, NCCN clinical practice guidelines in oncology.
J Natl Compr Canc Netw
2016; 14:
1286–1312.27697982,
AjaniJA
D’AmicoTA
AlmhannaK
, et al. Gastric cancer, version
3.2016, NCCN clinical practice guidelines in oncology.
J Natl Compr Canc Netw
2016; 14:
1286–1312.27697982
-
(
SmythEC
VerheijM
AllumW
, et al. Gastric cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol
2016; 27:
v38–v49.27664260)
SmythEC
VerheijM
AllumW
, et al. Gastric cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol
2016; 27:
v38–v49.27664260
SmythEC
VerheijM
AllumW
, et al. Gastric cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol
2016; 27:
v38–v49.27664260,
SmythEC
VerheijM
AllumW
, et al. Gastric cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol
2016; 27:
v38–v49.27664260
-
Japanese
Association
(2016)
Japanese gastric cancer treatment guidelines 2014 (ver. 4)
Gastric Cancer, 20
-
I.
Chau,
A.
Norman,
D.
Cunningham,
J.
Waters,
J.
Oates,
P.
Ross
(2004)
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 22 12
-
(
BergerY
GiurcanuM
ViningCC
, et al. Cytoreductive surgery for
selected patients whose metastatic gastric cancer was treated with systemic
chemotherapy. Ann Surg Oncol. Epub ahead of
print 8
January
2021. DOI: 10.1245/s10434-020-09475-6.)
BergerY
GiurcanuM
ViningCC
, et al. Cytoreductive surgery for
selected patients whose metastatic gastric cancer was treated with systemic
chemotherapy. Ann Surg Oncol. Epub ahead of
print 8
January
2021. DOI: 10.1245/s10434-020-09475-6.
BergerY
GiurcanuM
ViningCC
, et al. Cytoreductive surgery for
selected patients whose metastatic gastric cancer was treated with systemic
chemotherapy. Ann Surg Oncol. Epub ahead of
print 8
January
2021. DOI: 10.1245/s10434-020-09475-6.,
BergerY
GiurcanuM
ViningCC
, et al. Cytoreductive surgery for
selected patients whose metastatic gastric cancer was treated with systemic
chemotherapy. Ann Surg Oncol. Epub ahead of
print 8
January
2021. DOI: 10.1245/s10434-020-09475-6.
-
H.
Sung,
J.
Ferlay,
R.
Siegel,
M.
Laversanne,
I.
Soerjomataram,
A.
Jemal,
F.
Bray
(2021)
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
CA: A Cancer Journal for Clinicians, 71
-
R.
Warschkow,
M.
Baechtold,
K.
Leung,
B.
Schmied,
D.
Nussbaum,
B.
Gloor,
Dan
Iii,
M.
Worni
(2018)
Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population
Gastric Cancer, 21
-
(2016)
Gastrectomy plus chemotherapy versus journals.sagepub.com/home/tam single non-curable factor (REGATTA): a phase 3, randomised controlled trial
-
(
Van CutsemE
CervantesA
AdamR
, et al. ESMO consensus guidelines
for the management of patients with metastatic colorectal
cancer. Ann Oncol
2016; 27:
1386–1422.27380959)
Van CutsemE
CervantesA
AdamR
, et al. ESMO consensus guidelines
for the management of patients with metastatic colorectal
cancer. Ann Oncol
2016; 27:
1386–1422.27380959
Van CutsemE
CervantesA
AdamR
, et al. ESMO consensus guidelines
for the management of patients with metastatic colorectal
cancer. Ann Oncol
2016; 27:
1386–1422.27380959,
Van CutsemE
CervantesA
AdamR
, et al. ESMO consensus guidelines
for the management of patients with metastatic colorectal
cancer. Ann Oncol
2016; 27:
1386–1422.27380959
-
T.
Yoshino,
D.
Arnold,
H.
Taniguchi,
G.
Pentheroudakis,
K.
Yamazaki,
Rui-Hua
Xu,
Tae
Kim,
F.
Ismail,
I.
Tan,
K.
Yeh,
A.
Grothey,
S.
Zhang,
J.
Ahn,
M.
Mastura,
D.
Chong,
L.
Chen,
S.
Kopetz,
T.
Eguchi-Nakajima,
H.
Ebi,
A.
Ohtsu,
A.
Cervantes,
K.
Muro,
J.
Tabernero,
H.
Minami,
F.
Ciardiello,
J.
Douillard
(2018)
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS
Annals of Oncology, 29
-
(
SpiegelmanD
HertzmarkE
. Easy SAS calculations for risk or prevalence
ratios and differences. Am J Epidemiol
2005; 162:
199–200.15987728)
SpiegelmanD
HertzmarkE
. Easy SAS calculations for risk or prevalence
ratios and differences. Am J Epidemiol
2005; 162:
199–200.15987728
SpiegelmanD
HertzmarkE
. Easy SAS calculations for risk or prevalence
ratios and differences. Am J Epidemiol
2005; 162:
199–200.15987728,
SpiegelmanD
HertzmarkE
. Easy SAS calculations for risk or prevalence
ratios and differences. Am J Epidemiol
2005; 162:
199–200.15987728
-
C.
Gara,
J.
Hanson,
S.
Hamilton
(2003)
A population-based study of tumor-node relationship, resection margins, and surgeon volume on gastric cancer survival.
American journal of surgery, 186 1
-
F.
Coccolini,
Eddy
Cotte,
O.
Glehen,
M.
Lotti,
E.
Poiasina,
F.
Catena,
Y.
Yonemura,
L.
Ansaloni
(2013)
Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 40 1
-
Jian-zhong
Zhang,
Hui-shan
Lu,
Chang-ming
Huang,
Xing-Yuan
Wu,
Chuang
Wang,
G.
Guan,
Jian
Zhen,
He-guang
Huang,
Xian-Fu
Zhang
(2011)
Outcome of palliative total gastrectomy for stage IV proximal gastric cancer.
American journal of surgery, 202 1
-
D.
Cunningham,
N.
Starling,
S.
Rao,
T.
Iveson,
M.
Nicolson,
F.
Coxon,
G.
Middleton,
F.
Daniel,
J.
Oates,
A.
Norman
(2008)
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
The New England journal of medicine, 358 1
-
(
MezhirJJ
ShahMA
JacksLM
, et al. Positive peritoneal cytology
in patients with gastric cancer: natural history and outcome of 291
patients. Ann Surg Oncol
2010; 17:
3173–3180.20585870)
MezhirJJ
ShahMA
JacksLM
, et al. Positive peritoneal cytology
in patients with gastric cancer: natural history and outcome of 291
patients. Ann Surg Oncol
2010; 17:
3173–3180.20585870
MezhirJJ
ShahMA
JacksLM
, et al. Positive peritoneal cytology
in patients with gastric cancer: natural history and outcome of 291
patients. Ann Surg Oncol
2010; 17:
3173–3180.20585870,
MezhirJJ
ShahMA
JacksLM
, et al. Positive peritoneal cytology
in patients with gastric cancer: natural history and outcome of 291
patients. Ann Surg Oncol
2010; 17:
3173–3180.20585870
-
E.
Cutsem,
A.
Cervantes,
René
Adam,
A.
Sobrero,
J.
Krieken,
D.
Aderka,
E.
Aguilar,
A.
Bardelli,
A.
Benson,
G.
Bodoky,
F.
Ciardiello,
A.
D'Hoore,
E.
Díaz-Rubio,
J.
Douillard,
M.
Ducreux,
A.
Falcone,
A.
Grothey,
T.
Gruenberger,
K.
Haustermans,
V.
Heinemann,
P.
Hoff,
C.
Köhne,
R.
Labianca,
P.
Laurent-Puig,
B.
Ma,
T.
Maughan,
K.
Muro,
N.
Normanno,
P.
Österlund,
P.
Österlund,
W.
Oyen,
D.
Papamichael,
G.
Pentheroudakis,
P.
Pfeiffer,
T.
Price,
C.
Punt,
J.
Ricke,
A.
Roth,
R.
Salazar,
W.
Scheithauer,
H.
Schmoll,
J.
Tabernero,
J.
Taieb,
S.
Tejpar,
H.
Wasan,
T.
Yoshino,
A.
Zaanan,
D.
Arnold
(2016)
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, 27 8
-
M.
Messager,
J.
Lefèvre,
V.
Pichot-Delahaye,
A.
Souadka,
G.
Piessen,
C.
Mariette,
J.
Arnaud,
J.
Balon,
F.
Bonnetain,
F.
Borie,
D.
Brachet,
C.
Brigand,
N.
Carrère,
X.
D'Journo,
P.
Dechelotte,
J.
Delpero,
Abdenaceur
Dhari,
S.
Fabre,
M.
Fernández,
R.
Flamein,
B.
Gillet,
A.
Glaise,
O.
Glehen,
D.
Goéré,
M.
Guilbert,
J.
Guiramand,
M.
Hebbar,
N.
Huten,
K.
Kraft,
E.
Leteurtre,
D.
Louis,
J.
Mabrut,
Benjamin
Mathieu,
B.
Meunier,
S.
Michalak,
F.
Michot,
B.
Millat,
F.
Paye,
F.
Peschaud,
D.
Pezet,
M.
Pocard,
A.
Poisson,
M.
Prudhomme,
J.
Regimbeau,
Timothée
Thiébot,
P.
Thomas,
B.
Tsilividis,
F.
Vandois
(2011)
The Impact of Perioperative Chemotherapy on Survival in Patients With Gastric Signet Ring Cell Adenocarcinoma: A Multicenter Comparative Study
Annals of Surgery, 254
-
(
BoucheO
RaoulJL
BonnetainF
, et al. Randomized multicenter phase
II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),
LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously
untreated metastatic gastric cancer: a Federation Francophone de
Cancerologie Digestive Group Study–FFCD 9803. J Clin
Oncol
2004; 22:
4319–4328.15514373)
BoucheO
RaoulJL
BonnetainF
, et al. Randomized multicenter phase
II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),
LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously
untreated metastatic gastric cancer: a Federation Francophone de
Cancerologie Digestive Group Study–FFCD 9803. J Clin
Oncol
2004; 22:
4319–4328.15514373
BoucheO
RaoulJL
BonnetainF
, et al. Randomized multicenter phase
II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),
LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously
untreated metastatic gastric cancer: a Federation Francophone de
Cancerologie Digestive Group Study–FFCD 9803. J Clin
Oncol
2004; 22:
4319–4328.15514373,
BoucheO
RaoulJL
BonnetainF
, et al. Randomized multicenter phase
II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2),
LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously
untreated metastatic gastric cancer: a Federation Francophone de
Cancerologie Digestive Group Study–FFCD 9803. J Clin
Oncol
2004; 22:
4319–4328.15514373
-
(
WagnerAD
SynNL
MoehlerM
, et al. Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev
2017; 8: CD004064.)
WagnerAD
SynNL
MoehlerM
, et al. Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev
2017; 8: CD004064.
WagnerAD
SynNL
MoehlerM
, et al. Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev
2017; 8: CD004064.,
WagnerAD
SynNL
MoehlerM
, et al. Chemotherapy for advanced
gastric cancer. Cochrane Database Syst Rev
2017; 8: CD004064.
-
S.
Al-Batran,
E.
Jäger,
M.
Scholz
(2007)
Chemotherapy for advanced gastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 6
-
(
LiQ
ZouJ
JiaM
, et al. Palliative gastrectomy and
survival in patients with metastatic gastric cancer: a propensity
score-matched analysis of a large population-based study.
Clin Transl Gastroenterol
2019; 10:
1–8.)
LiQ
ZouJ
JiaM
, et al. Palliative gastrectomy and
survival in patients with metastatic gastric cancer: a propensity
score-matched analysis of a large population-based study.
Clin Transl Gastroenterol
2019; 10:
1–8.
LiQ
ZouJ
JiaM
, et al. Palliative gastrectomy and
survival in patients with metastatic gastric cancer: a propensity
score-matched analysis of a large population-based study.
Clin Transl Gastroenterol
2019; 10:
1–8.,
LiQ
ZouJ
JiaM
, et al. Palliative gastrectomy and
survival in patients with metastatic gastric cancer: a propensity
score-matched analysis of a large population-based study.
Clin Transl Gastroenterol
2019; 10:
1–8.
-
Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial
-
(
ThrumurthySG
ChaudryMA
HochhauserD
, et al. The diagnosis and management
of gastric cancer. BMJ
2013; 347: f6367.24191271)
ThrumurthySG
ChaudryMA
HochhauserD
, et al. The diagnosis and management
of gastric cancer. BMJ
2013; 347: f6367.24191271
ThrumurthySG
ChaudryMA
HochhauserD
, et al. The diagnosis and management
of gastric cancer. BMJ
2013; 347: f6367.24191271,
ThrumurthySG
ChaudryMA
HochhauserD
, et al. The diagnosis and management
of gastric cancer. BMJ
2013; 347: f6367.24191271
-
N.
Charalampakis,
G.
Gonzalez,
E.
Elimova,
R.
Wadhwa,
H.
Shiozaki,
Yusuke
Shimodaira,
M.
Blum,
J.
Rogers,
K.
Harada,
Aurelio
Jr.,
Tara
Sagebiel,
P.
Das,
B.
Minsky,
Jeffrey
Lee,
B.
Weston,
M.
Bhutani,
J.
Estrella,
B.
Badgwell,
J.
Ajani
(2016)
The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation
Oncology, 90
-
(
Al-BatranSE
HomannN
PauligkC
, et al. Effect of neoadjuvant
chemotherapy followed by surgical resection on survival in patients with
limited metastatic gastric or gastroesophageal junction cancer: the
AIO-FLOT3 trial. JAMA Oncol
2017; 3:
1237–1244.28448662)
Al-BatranSE
HomannN
PauligkC
, et al. Effect of neoadjuvant
chemotherapy followed by surgical resection on survival in patients with
limited metastatic gastric or gastroesophageal junction cancer: the
AIO-FLOT3 trial. JAMA Oncol
2017; 3:
1237–1244.28448662
Al-BatranSE
HomannN
PauligkC
, et al. Effect of neoadjuvant
chemotherapy followed by surgical resection on survival in patients with
limited metastatic gastric or gastroesophageal junction cancer: the
AIO-FLOT3 trial. JAMA Oncol
2017; 3:
1237–1244.28448662,
Al-BatranSE
HomannN
PauligkC
, et al. Effect of neoadjuvant
chemotherapy followed by surgical resection on survival in patients with
limited metastatic gastric or gastroesophageal junction cancer: the
AIO-FLOT3 trial. JAMA Oncol
2017; 3:
1237–1244.28448662
-
S.
Al-Batran,
N.
Homann,
C.
Pauligk,
G.
Illerhaus,
U.
Martens,
J.
Stoehlmacher,
H.
Schmalenberg,
K.
Luley,
N.
Prasnikar,
M.
Egger,
S.
Probst,
H.
Messmann,
M.
Moehler,
W.
Fischbach,
J.
Hartmann,
F.
Mayer,
H.
Höffkes,
M.
Koenigsmann,
D.
Arnold,
T.
Kraus,
Kersten
Grimm,
Stefan
Berkhoff,
S.
Post,
E.
Jäger,
W.
Bechstein,
U.
Ronellenfitsch,
S.
Mönig,
R.
Hofheinz
(2017)
Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial
JAMA Oncology, 3
-
(
D’UgoD
CananziFC
PersianiR
, et al. REGATTA trial: a call for
the USA and Europe. Lancet Oncol
2016; 17:
261–262.26972851)
D’UgoD
CananziFC
PersianiR
, et al. REGATTA trial: a call for
the USA and Europe. Lancet Oncol
2016; 17:
261–262.26972851
D’UgoD
CananziFC
PersianiR
, et al. REGATTA trial: a call for
the USA and Europe. Lancet Oncol
2016; 17:
261–262.26972851,
D’UgoD
CananziFC
PersianiR
, et al. REGATTA trial: a call for
the USA and Europe. Lancet Oncol
2016; 17:
261–262.26972851
-
(
ChauI
NormanAR
CunninghamD
, et al. Multivariate prognostic
factor analysis in locally advanced and metastatic esophago-gastric
cancer–pooled analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol
2004; 22:0
2395–2403.15197201)
ChauI
NormanAR
CunninghamD
, et al. Multivariate prognostic
factor analysis in locally advanced and metastatic esophago-gastric
cancer–pooled analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol
2004; 22:0
2395–2403.15197201
ChauI
NormanAR
CunninghamD
, et al. Multivariate prognostic
factor analysis in locally advanced and metastatic esophago-gastric
cancer–pooled analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol
2004; 22:0
2395–2403.15197201,
ChauI
NormanAR
CunninghamD
, et al. Multivariate prognostic
factor analysis in locally advanced and metastatic esophago-gastric
cancer–pooled analysis from three multicenter, randomized, controlled trials
using individual patient data. J Clin Oncol
2004; 22:0
2395–2403.15197201
-
Y.
Berger,
M.
Giurcanu,
C.
Vining,
D.
Schuitevoerder,
M.
Posner,
K.
Roggin,
B.
Polite,
C.
Liao,
O.
Eng,
D.
Catenacci,
K.
Turaga
(2021)
Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy
Annals of Surgical Oncology, 28